Little was known about iodine metabolism in the mid-1930s, but 
INTRODUCTION
sands of readers who got that issue saw that the two papers were oddly similar: the papers reported patients from There were two papers on a new treatment, radioac-the same unit, the Thyroid Clinic at Boston's MGH who tive iodine, for the hyperthyroidism of Graves' disease were given the same radioiostope of iodine, 130I. Further, in the weekly issue of the Journal of the American Med-the radioiodine came from the same source, the MIT cyical Association (JAMA) of May 11, 1946 (1, 2) . The thou-clotron, and both papers acknowledged the same mentor, 'Medical Service, Boston Veterans Affairs Medical Center, Boston, Massachusetts. 2Department of Medicine, Boston University School of Medicine, Boston, Massachusetts. 3Division of Nuclear Medicine, Department of Radiology, New York Hospital-Cornell Medical Center, New York, New York. *Presented in part at the International Symposium on Radioiodine, Mayo Clinic, Rochester, Minnesota, 1996 (C.T.S.), and as the Presidential Address, American Thyroid Association, 1983 (D.V.B.).
J. Howard Means (1885 Means ( -1967 , then the chief of the Medical Service at MGH, a professor of medicine at Harvard's medical school, and a leading American thyroidologist although he was not a coauthor of either paper. Despite these similarities, and even more oddly, the two papers were written by two completely different physician-physicist teams; one was by the physician Saul Hertz and the physicist Arthur Roberts (1912-) and the other by the physician Earle Chapman ) and the physicist Robley Evans .
One well might wonder how two papers so similar could be written by two different sets of authors. Behind the two papers is the story of an innovative collaboration that not only melded physics and medicine to develop a successful therapy, now the most common treatment for hyperthyroidism in the United States, but also led to personality clashes, wounded egos, and a claim of academic theft.
BACKGROUND
The two 1946 papers on the radioiodine treatment of hyperthyroidism appeared 10 years after the Boston investigators first thought in 1936 that radioiodine might lead to such a treatment. The idea itself, however, did not spring from their minds de novo but was rooted in several antecedents in the science and medicine of the day. These were [1] the knowledge that the thyroid gland concentrates iodine, [2] the idea that tracer substances could be used to analyze biologic functions, [3] the discovery of artificial radioactivity, and [4] the knowledge that external x-irradiation could benefit hyperthyroidism.
Iodine and the thyroid gland By the mid-1930s, any scientist or physician interested in the thyroid gland knew that it contained iodine, that it took up and concentrated iodine, and that its hormone (they only knew of one) was made up mostly of iodine. They knew, for example, that a German biochemist, Eugen Baumann (1846-1896), had found iodine in the thyroid gland in 1895, more or less by informed accident (3) ; that Edward Kendall had isolated "the" thyroid hormone at the Mayo Clinic in 1914 by using iodine as a marker for the hormone (4) (unfortunately for Kendall, he proposed the wrong chemical structure, which was correctly determined by Charles Harington (1897 Harington ( -1972 in 1926 [5] ); and that David Marine in 1915, then in Cleveland, showed that the thyroid gland took up stable iodine from a perfusate when studied in vitro (6) .
Clearly iodine metabolism was a dynamic key to how and why the thyroid gland functioned, but in The concept of biologic tracers György Hevesy (1885 Hevesy ( -1966 established the idea of using a "marker" or a tracer substance to assess biologic function a decade before the 1930s. Hevesy came to this idea because of his work with radioactive lead in [1911] [1912] . Charged then with the task of separating "radium D" from lead so that the radium D could be used for radiation studies, he was unable to separate the two. Eventually the reason became clear: radium D was in fact radioactive lead. So, rather than trying to separate it from lead, he turned its inseparability to advantage, using it as a marker or tracer for lead itself in chemical work (7) . In 1923 he turned to biology and showed that plant roots were able to take up and release this naturally radioactive lead (8) (in 1943 he won a Nobel prize for his work). The radioactive lead was different from other lead atoms in that it was radioactive, but the two were treated by the plant identically. At the same time, the ability to detect it by measuring its radioactivity meant that one needed only a small amount and so one could avoid the potential interference of a large amount with the plant's natural processes.
Hevesy realized that the ideal tracer for any biologic process would be an element or a compound that was similar enough to a known biologic substance that it would be treated by the organism as if it actually were the known substance and yet different enough that it could be detected separately from the known substance. The marker, or tracer, also needed to be present in only small amounts, so there had to be a highly sensitive method to detect the tracer. The tracer would be like a reporter: it would not affect a biologic process, because there was so little of it, but, because the tracer would be metabolized in the same way as the substance it was tracing, it would tell us how the process functioned.
However, once Hevesy established the principle, he faced the problem of applying it to biology in general or to medicine in particular. The problem at the time was essentially insoluble; there were then only a few known radioactive substances that could be used, and none were common biologic elements. The naturally radioactive lead was one; radon, which actually was used in humans to test the circulation time of the blood, and bismuth were others. There was no radioactive iodine.
The discovery of artificial radioactivity Only 2 years before the Boston investigators had their idea about radioiodine in 1936, the Parisian husband and wife physicist team Frédéric Joliot 35 -45% of the radioactivity was in the thyroid gland, as they had hoped, and most of the rest (40-50%) was in the urine. That winter they studied 48 rabbits; some were normal and some had artificial thyroid hyperplasia induced by injections of thyrotropin (TSH) (Hertz had been studying the effect of TSH on thyroid histology for several years on the then-common assumption that TSH-induced hyperplasia was an animal model of Graves' hyperthyroidism [15] Means confirmed the rabbit work with these longer-lasting radioiodine isotopes. They also were able to make an important finding: the rabbit's thyroid gland took up more radioiodine if they gave it with only a small amount of stable, nonradioactive iodide than if they gave it with a large amount of carrier (note that all four were now coauthors) (18) . They clearly recognized that the "carrier" iodide lowered the thyroid uptake of the radioiodide. They did not forget the therapeutic potential, but at the time their calculation of what it would take to treat a patient was discouraging; they estimated that with the rapidly decaying 128I it would take the impossibly large amount of 750 mCi to treat hyperthyroidism.
Throughout 1939 and most of 1940, they stuck to the study of rabbits; they did not give radioiodine to humans.
Hertz was working full-time in Means' department but still on a periodically renewable appointment as was the custom (permanent jobs in academic medicine were few then). Means box and then drank the radioactive sodium. Hamilton also studied radioiodine (128I), which was absorbed from the gut in "3 to 6 minutes" (20) . As (23) . Most of the radioiodine went into the urine of each of these patients and there was no clear difference between those with and without thyroid disease; they must have been disappointed (in retrospect, we now know that 14 mg is quite a large amount of stable iodine and that it "swamped" their radioiodine). They nevertheless were able to show that if the thyroid tissue removed at surgery 2 days after giving the radioiodine was hyperplastic, it had more radioiodine in it. The one cancerous thyroid tissue removed surgically after giving radioiodine contained little radioactivity. With the use of a Geiger counter, they showed that some of the radioiodine was taken up by the thyroid gland; although the result was not quantitative and they did this in only one patient, this seems to have been the first attempt at an "uptake test" in a human. They could draw no substantial conclusions in 1939, but they had done human studies for the first time with the radioiodine, 131I, we still use for therapy.
Hamilton and Soley, using the relatively long-lasting 131I, went on to show systematic radioiodine uptake by the human thyroid gland over several days (24 Hertz (41) and Chapman (42) (46) 
